ReviewJournal of the Society for Cardiovascular Angiography & Interventions2026
Mitral Transcatheter Edge-to-Edge Repair Versus Guideline-Directed Medical Therapy for Functional Mitral Regurgitation With Heart Failure: An Updated Meta-analysis.
Review in Journal of the Society for Cardiovascular Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mitral transcatheter edge-to-edge repair (MTEER) and guideline-directed medical therapy (GDMT) may be used to treat functional mitral regurgitation (FMR) with heart failure (HF). The optimal management of FMR is unclear. Methods: We performed a contemporary systematic review and meta-analysis comparing MTEER vs GDMT. PubMed, Embase, and Cochrane Central were systematically searched for randomized controlled trials and propensity score matched studies comparing outcomes of MTEER plus GDMT vs GDMT alone in FMR with HF. Odds ratios and risk ratios (RRs) with 95% CI were estimated using random-effects models. Results: Three randomized controlled trials and 5 propensity score matched studies were identified (n = 2588) comparing MTEER (52.2%) vs GDMT alone (47.8%) for FMR with HF. MTEER was associated with lower risks of 12-month all-cause mortality (RR, 0.74; 95% CI, 0.58-0.95; Conclusion: MTEER reduced all-cause cardiovascular mortality and HF hospitalization in patients with FMR and HF compared with GDMT alone. Additionally, MTEER resulted in a significant improvement in functional status in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.